A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

NCT07545044 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Recurrent or Metastatic Breast Cancer

Interventions

DRUG: JSKN003
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Docetaxel

Sponsor

Shanghai JMT-Bio Inc.